CervoMed will present Phase 2b study results for neflamapimod in dementia with Lewy bodies at an upcoming conference.
Quiver AI Summary
CervoMed Inc. announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025. The study investigates neflamapimod as a treatment for dementia with Lewy bodies (DLB) and initial results were previously shared on December 10, 2024. The oral presentation will be led by Dr. John Alam, CEO of CervoMed and a co-principal investigator of the study. More information about the presentation will be available on CervoMed's website after the event. The company focuses on developing treatments for age-related neurologic disorders, with neflamapimod aimed at addressing synaptic dysfunction associated with various neurological diseases.
Potential Positives
- Topline results from a key Phase 2b clinical study will be presented at a prominent international conference, raising visibility and credibility for CervoMed.
- The presentation of initial results for the RewinD-LB study, focusing on dementia with Lewy bodies, signifies progress in the development of a potentially impactful treatment.
- The participation of CervoMed's CEO, who is also a co-principal investigator of the study, underscores the company's commitment and expertise in this research area.
Potential Negatives
- Delayed presentation of topline results could indicate unresolved issues or concerns regarding the efficacy and safety of neflamapimod.
- The upcoming presentation at the ILBDC may not meet investor expectations if the results are not favorable, potentially impacting stock performance.
- The reliance on a single product, neflamapimod, increases risk for the company if the clinical trials do not yield positive outcomes.
FAQ
What is the Phase 2b RewinD-LB study about?
The Phase 2b RewinD-LB study evaluates the efficacy and safety of neflamapimod in treating dementia with Lewy bodies.
When will the topline results be presented?
The topline results will be presented on January 31, 2025, at the 8th International Lewy Body Dementia Conference in Amsterdam.
Who is presenting the topline results?
The topline results will be presented by John Alam, MD, the CEO of CervoMed and co-principal investigator of the study.
Where can I find more details about the presentation?
Details of the presentation will be available in the Investor section of the CervoMed website following the event.
What is the goal of CervoMed?
CervoMed aims to develop treatments for age-related neurologic disorders, focusing on innovative therapies like neflamapimod for major neurological conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRVO Insider Trading Activity
$CRVO insiders have traded $CRVO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CRVO stock by insiders over the last 6 months:
- WILLIAM ROBERT ELDER (CFO & GC) purchased 1,000 shares for an estimated $18,160
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRVO Hedge Fund Activity
We have seen 28 institutional investors add shares of $CRVO stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 238,000 shares (-37.2%) from their portfolio in Q3 2024, for an estimated $3,474,800
- AWM INVESTMENT COMPANY, INC. added 134,966 shares (+43.0%) to their portfolio in Q3 2024, for an estimated $1,970,503
- PERIGON WEALTH MANAGEMENT, LLC added 62,729 shares (+inf%) to their portfolio in Q4 2024, for an estimated $146,785
- NORTHERN TRUST CORP added 53,692 shares (+inf%) to their portfolio in Q3 2024, for an estimated $783,903
- MORGAN STANLEY added 37,436 shares (+488.3%) to their portfolio in Q3 2024, for an estimated $546,565
- IKARIAN CAPITAL, LLC removed 35,000 shares (-14.7%) from their portfolio in Q3 2024, for an estimated $511,000
- STATE STREET CORP added 22,903 shares (+28.1%) to their portfolio in Q3 2024, for an estimated $334,383
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8 th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here .
Details of the ILBDC presentation are as follow:
Abstract Title:
Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format:
Oral Presentation
Presenter:
John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study
Session Name:
Symposium VIII-Therapy
Session Date and Time:
Friday, January 31, 2025, 13:30pm CET / 7:30am ET
The details of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation.
About CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in certain major neurological disorders.
Investor Contact:
PJ Kelleher
LifeSci Advisors
[email protected]
617-430-7579